Navigation Links
Sorrento Therapeutics Receives Frost & Sullivan's 2013 Global Investment Opportunity Award in Oncology
Date:6/6/2013

SAN DIEGO, June 6, 2013 /PRNewswire/ -- Sorrento Therapeutics, Inc. (OTCBB: SRNE) today announced that it has been awarded the 2013 Frost & Sullivan Global Investment Opportunity Award in Oncology.

In the citation for the 2013 Global Investment Opportunity Award in Oncology, Frost & Sullivan highlights Sorrento's diverse G-MAB® library technology, the experienced management team, and its ability to select and rapidly develop promising drug candidates, such as the late-stage oncolytic product candidate Cynviloq™—a next-generation branded paclitaxel formulation to be exclusively marketed and distributed by IGDRASOL, Inc. in the U.S. and 27 EU countries, if approved—and fully human anti-PD-L1 and anti-PD-1 monoclonal antibodies (mAbs) in oncology. Sorrento has the right to acquire IGDRASOL pursuant to a previously announced option agreement, entered into in March 2013. Taken together, these unique characteristics make "Sorrento Therapeutics the rightful recipient of the 2013 Frost & Sullivan Global Investment Opportunity Award" as the award report concludes.

"We are honored that the distinguished and independent global analyst firm Frost & Sullivan has recognized our achievements as well as our potential, and emphasizes the value our technologies and expertise have created," said Henry Ji , Ph.D., Sorrento's president and CEO. "We believe this award validates our corporate strategy. We are rapidly moving forward to develop our lead product candidates, including Cynviloq™ and our fully human antibody drug candidates targeting PD-L1 and PD-1, which we believe are very promising and exciting targets in the fast-growing market of immunomodulatory cancer therapy."

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation and implementation of powerful growth strategies. Frost & Sullivan leverages 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 40 offices on six continents. To join Frost & Sullivan's Growth Partnership, please visit http://www.frost.com.

About Sorrento Therapeutics, Inc.

Sorrento Therapeutics, Inc. is a publicly-traded, development-stage biopharmaceutical company focused on the acquisition, discovery, development and commercialization of novel and proprietary therapeutics for the treatment of a variety of disease conditions, including cancer, inflammation, metabolic and infectious diseases. Sorrento's objectives are, assuming its acquisition of IGDRASOL: (i) to develop and commercialize its late-stage, oncolytic drug candidate Cynviloq™ for multiple cancer indications, and (ii) to identify drug development candidates derived from its proprietary human antibody libraries and, either independently or through partnerships, advance selected targets into preclinical or clinical development. In 2012, Sorrento identified and further developed a number of potential drug product candidates across various therapeutic areas. Sorrento intends to select several lead product candidates to progress into preclinical development activities in 2013, including human anti-PD-L1 and anti-PD-1 monoclonal antibodies (mAbs) that have demonstrated strong immunomodulatory activity in vitro comparable to competitor mAbs currently in clinical development as well as significant anti-cancer activity in a tumor mouse model.

Forward-Looking Statements

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Words such as "assumes," "plans," "believes," "expects," "anticipates," and "will," and similar expressions, are intended to identify forward-looking statements. Forward-looking statements include statements about the clinical development and commercial potential for Cynviloq™, the potential combination of Sorrento and IGDRASOL, and the preclinical and clinical development of Sorrento's human antibody therapeutics. All such forward-looking statements are based on Sorrento's current beliefs and expectations, and should not be regarded as a representation by Sorrento that any of its plans will be achieved. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in Sorrento's businesses; the scope and validity of patent protection for Sorrento's platform technologies, and the risk that the development or commercialization of product candidates may infringe the intellectual property rights of others; the potential that Sorrento may require substantial additional funding in order to obtain regulatory approval for and commercialize quorum quenching technologies or any other product; and additional risks set forth in Sorrento's Form 10-K for the year ended December 31, 2012, and other periodic reports filed with the Securities and Exchange Commission. These forward-looking statements represent Sorrento's judgment as of the date of this release. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Sorrento undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.


'/>"/>
SOURCE Sorrento Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Sorrento Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference in New York City
2. Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases
3. Sorrento Therapeutics, Inc. and IGDRASOL Announce Presentation on Non-Biologic Nanoparticle paclitaxel (NBN-Pac) Formulations for the Treatment of Solid Tumors at the Nanomedicine 2013 Meeting in Barcelona, Spain
4. Sorrento Therapeutics Signs Exclusive Option to Acquire IGDRASOL
5. Sorrento Therapeutics Awarded Third Phase I STTR Grant
6. Prime Therapeutics specialty pharmacy receives URAC accreditation
7. Novira Therapeutics Expands Management Team with Appointment of Klaus Klumpp, Ph.D., the Former Global Head of Roches Virology Discovery Initiatives, as Vice President Discovery Research
8. Analysis and Forecasts of the Amyotrophic Lateral Sclerosis Therapeutics Market
9. Protagonist Therapeutics Raises $14 Million in Series B Venture Financing
10. Tunitas Therapeutics Awarded Phase II SBIR Grant to Advance Asthma Program
11. Prime Therapeutics appoints Scott Fries as senior vice president of government programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... Dec. 8, 2016 Australia Glaucoma Surgery ... GlobalData,s new report, "Australia Glaucoma Surgery Devices Market ... the Australia Glaucoma Surgery Devices market. The report ... (in units) and average prices (USD) within market ... also provides company shares and distribution shares data ...
(Date:12/8/2016)... KEY FINDINGS The global medical lifting sling ... for growth of the medical lifting sling market are ... high recovery cost of injuries and government initiatives to ... refers to an assistive device that helps caregiver transfer ... the lift and hold the patient. It is important ...
(Date:12/8/2016)... INDIANAPOLIS , Dec. 8, 2016  Eli Lilly ... detailed results of its phase 3 EXPEDITION3 trial at ... (CTAD) meeting. As previously disclosed, solanezumab did not meet ... study of solanezumab initiated in people with mild dementia ... pursue regulatory submissions for solanezumab for the treatment of ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... December 08, 2016 , ... Mirixa Corporation ... adherence, and other pharmacist-delivered patient care services, has announced the promotions of Karen ... to vice president of sales. , Litsinger joined Mirixa in 2008 after ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... David ... with global law firm Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. 12, ... of the DeviceTalks series, and attorneys from the firm’s global Life Sciences & Medical ...
(Date:12/8/2016)... ... December 08, 2016 , ... Launching ... innovative Unified Instance Manager architecture, meeting the needs of multichannel growth and ... the unattended auto-dialing system without agents, Presence Robodialer, provides greater operational capacity, ...
(Date:12/8/2016)... ... December 08, 2016 , ... STAT courier is pleased to announce that ... for Texas, they are expanding their presence in Dallas. One of the most exciting ... bring new jobs to the Dallas and Forth Worth market. STAT takes pride in ...
(Date:12/8/2016)... ... December 08, 2016 , ... Healthcare is ... Dr. Botelho advocates for the mass media launching of story movements to highlight ... to share their unfortunate experiences; such a movement can generate the network power ...
Breaking Medicine News(10 mins):